Pleasant news brings to the fore regarding him coronavirus the pharmaceutical company Merck which announced that the experimental pill he developed reduces hospitalizations and deaths by 50%.
According to the company and as reported by the Associated Press, the drug was particularly effective in people who they received it just five days after the onset of the first symptoms of coronavirus.
The people who received this news pill against coronavirus had about half the hospitalization and death rate compared to patients receiving a placebo preparation.
The pill is called “molnupiravir” and the company that developed it is expected to immediately apply for its approval to the US health services and the rest of the world.
If approved, it will be the first drug to be released as a treatment for coronavirus
According to the Associated Press, if the pill is approved, it will be the first will be released as a treatment for coronavirus.
«It could potentially be a significant step forward in efforts to combat the pandemic. “All coronavirus treatments currently used in the United States are administered intravenously or by injection.”
Merck, which works with Ridgeback Biotherapeutics, points out that The scientists who conducted the study studied the behavior of 775 adults with mild to moderate COVID-19. These individuals were at high risk for serious illness as some were obese but suffered from diabetes and heart disease.
The results of the research were published by Merck itself and have not yet been evaluated by competent services.
“When you see a 50% reduction in hospitalization or death, that’s a significant clinical impact,” said Dr. Dean Lee, vice president of research at Merck.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
